Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2007 4
2008 2
2009 2
2010 2
2011 7
2012 13
2013 18
2014 23
2015 15
2016 8
2017 10
2018 9
2019 16
2020 21
2021 17
2022 16
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
Trial designs and endpoints for immune therapies in multiple myeloma.
Lancman G, Moshier E, Cho HJ, Parekh S, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez L, Jagannath S, Chari A. Lancman G, et al. Among authors: moshier e. Am J Hematol. 2023 Mar;98 Suppl 2:S35-S45. doi: 10.1002/ajh.26753. Epub 2022 Nov 7. Am J Hematol. 2023. PMID: 36200130 Free article. Review.
PD-1 inhibition in advanced myeloproliferative neoplasms.
Hobbs G, Cimen Bozkus C, Moshier E, Dougherty M, Bar-Natan M, Sandy L, Johnson K, Foster JE, Som T, Macrae M, Marble H, Salama M, El Jamal SM, Zubizarreta N, Wadleigh M, Stone R, Bhardwaj N, Iancu-Rubin C, Mascarenhas J. Hobbs G, et al. Among authors: moshier e. Blood Adv. 2021 Dec 14;5(23):5086-5097. doi: 10.1182/bloodadvances.2021005491. Blood Adv. 2021. PMID: 34581778 Free PMC article.
The effect of novel therapies in high-molecular-risk multiple myeloma.
Lancman G, Tremblay D, Barley K, Barlogie B, Cho HJ, Jagannath S, Madduri D, Moshier E, Parekh S, Chari A. Lancman G, et al. Among authors: moshier e. Clin Adv Hematol Oncol. 2017 Nov;15(11):870-879. Clin Adv Hematol Oncol. 2017. PMID: 29200420 Free PMC article. Review.
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, Thibaud S, Pan D, Rajeeve S, Agte S, Aleman A, Sanchez L, Richard S, Rossi A, Richter J, Cho HJ, Rodriguez C, Lagana A, Moshier E, Chari A, Jagannath S, Parekh S. Mouhieddine TH, et al. Among authors: moshier e. Blood Adv. 2023 Mar 28;7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923. Blood Adv. 2023. PMID: 36018226 Free PMC article. Clinical Trial.
Multicenter phase II trial of transanal total mesorectal excision for rectal cancer: preliminary results.
Sylla P, Sands D, Ricardo A, Bonaccorso A, Polydorides A, Berho M, Marks J, Maykel J, Alavi K, Zaghiyan K, Whiteford M, Mclemore E, Chadi S, Shawki SF, Steele S, Pigazzi A, Albert M, DeBeche-Adams T, Moshier E, Wexner SD. Sylla P, et al. Among authors: moshier e. Surg Endosc. 2023 Dec;37(12):9483-9508. doi: 10.1007/s00464-023-10266-9. Epub 2023 Sep 12. Surg Endosc. 2023. PMID: 37700015 Free PMC article. Clinical Trial.
Discordance in Total Mesorectal Excision Specimen Grading in a Prospective Phase 2 Multicenter Rectal Cancer Trial: Are We Overestimating the Quality of Our Resections?
Sylla P, Berho M, Sands D, Ricardo A, Bonaccorso A, Moshier E, Hain E, Letchinger R, Marks J, Whiteford M, Mclemore E, Maykel J, Alavi K, Zaghiyan K, Chadi S, Shawki SF, Steele S, Pigazzi A, Albert M, DeBeche-Adams T, Polydorides A, Wexner S. Sylla P, et al. Among authors: moshier e. Ann Surg. 2023 Sep 1;278(3):452-463. doi: 10.1097/SLA.0000000000005948. Epub 2023 Jul 17. Ann Surg. 2023. PMID: 37450694 Clinical Trial.
167 results